DUBLIN, September 28, 2021--(BUSINESS WIRE)--The "Syndromic Multiplex Diagnostic Markets 2021 - 2025" report has been added to ResearchAndMarkets.com's offering.
The report forecasts the market size out to 2025. In a special section, the report looks at the numbers on how syndromic molecular diagnostics is replacing traditional panel-based ordering of infectious disease tests.
The COVID pandemic is ushering in a new world of infectious disease diagnostics. Infectious disease Dx is changing and will change more in the future. Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Syndromic Multiplex Diagnostics.
Are targeted tests for specific pathogens going to be obsolete? Will diagnostics replace physicians? Will Infectious Disease testing move into the Physician's Office or even the Home?
Syndromic testing is proving itself in the market. Players are reporting double-digit growth. Lowering costs, improving outcomes and even helping in the battle against Anti Microbial Resistance. Learn about this market including the issues and outlooks.
The two key trends of Point of Care Testing and Molecular Diagnostics are merging with spectacular success. It could possibly displace most frontline test protocols AND save money at the same time.
Syndromic Testing Recent Developments
QuantuMDx Developing Syndromic Panels for European Launch
Quidel Gains CE Mark for Savanna Analyzer, Respiratory Panel
QuantuMDx Gets CE Mark for Rapid PoC PCR System
Bio-Rad Laboratories, Seegene Partner for MDx Development
Baebies to Expand Finder Platform
With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio
Binx Health Targeting Clinics, DTC & OTC With STI Tests
Luminex Lands BARDA Grant to Develop Test for SARS-CoV-2, Flu, RSV
Molzym, Fraunhofer Developing Rapid Sepsis Diagnostic
MiRxes Receives Approval for Multiplex SARS-CoV-2, Flu Test
New Approach Involves Silicon-Based Test for Infectious Disease Screening
Scanogen's Portable Battery Operated Instrument for 90 Minute Multiplex Test
Qiagen sees NeuMoDx as Growth Vehicle
Torus Biosystems Developing Syndromic Test with 30-Minute Turnaround
Roche, SpeeDx Partner to Expand Access to Antibiotic Resistance Tests
bioMerieux's BioFire SARS-CoV-2 Respiratory Panel Wins FDA EAU
Infectious Disease Testing Firm Curative Acquires KorvaLabs
ChromaCode Raises Additional $10M
COVID-19 Patients Need Syndromic Testing
GenMark Diagnostics - New Respiratory Panel due in June
Qiagen Respiratory Panel with Coronavirus Targets Receives CE Mark
Exact Diagnostics launches respiratory panel control
bioMerieux submits enhanced BioFire BCID2 Panel to FDA
Nanomix Receives CE Mark for Diagnostic
Applied BioCode Applies to FDA for Syndromic Respiratory Panel
Expedeon AG and Sona Nanotech to Collaborate on Multiplex POC
Qiagen's New GI Panel Performance Assessed
McKesson to Distribute QIAstat-Dx Syndromic Testing Solution in USA
Applied BioCode Obtains FDA Clearance
Meridian Bioscience to Acquire GenePOC Inc.
Curetis Introduces Rapid DNA Testing for Antibiotic Resistance
Qiagen gets FDA clearance for syndromic testing system
Entasis Therapeutics Signs Rapid Diagnostic Agreement with bioMerieux
Akonni Biosystems Submits Multiplex Diagnostics System to FDA
Ador Diagnostics to receive $30M in Funding for 100-Plex PoC
SAW Diagnostics Receives Funding for Commercialisation of PoC Platform
QuantuMDx and Molbio announce MoU
Immunexpress Wins $745K Contract for Rapid Sepsis Assay
Mobidiag Inks European, Middle Eastern Distribution Deals
BioFire FilmArray System chosen for Phase 3 clinical trial
Factors Driving Growth
Speed of Diagnosis.
Effect of Syndromic Testing on Costs.
Point of Care Advantage.
Syndrome Testing, Accuracy and Diagnostic Risk
Improvement in Outcomes.
Impact of the COVID-19 Pandemic.
Factors Limiting Growth
Infectious Disease is Declining But..
Economic Growth improves Living Standards.
Impact of the Pandemic Recession
Instrumentation and Automation
Instruments Key to Market Share
The Shrinking Machine.
Syndrome Testing Moving to Big Instruments?
Diagnostic Technology Development
Comparing Syndrome and Targeted Testing
The Multiplex Paradigm Shift
The Sepsis Testing Market - Bellwether for Syndromics
The Single Visit and AntiMicrobial Resistance
Syndromics drives POCT adoption.
A Big Future for PCR?
Profiles of Key Syndromic Testing Companies
Beckman Coulter Diagnostics
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc
BioFire Diagnostics (bioMerieux)
Bosch Healthcare Solutions GmbH
Credo Diagnostics Biomedical
Curetis N.V./Curetis GmbH
Enzo Life Sciences, Inc.
GenMark Dx (Roche)
Mesa Biotech (Thermo Fisher)
Oxford Nanopore Technologies
Roche Molecular Diagnostics
Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/jk1ojp
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005531/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900